Nonetheless, a follow-up therapeutic phase I/IIa study named “NeoRay” evaluated the safety, tolerability, pharmacokinetics, distribution, radiation dosimetry and anti-tumor activity of [177Lu]Lu-NeoBOMB1, amongst other cancers in BCa (HR positive, HER2 negative and HER2 low) (NCT03872778, ref. [27]). The gene discussed is ERBB2; the disease is cancer.